CDSCO panel approves Allergan Dexamethasone Intravitreal Implant for Diabetic Macular Edema
Advertisement
New Delhi: Based on the justification provided by the drug-maker Allergan India, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has given its nod for the additional indication for Dexamethasone Intravitreal Implant 0.7mg for the treatment of Diabetic Macular Edema(DME).
However, this approval is subjected to the condition that the firm should conduct active Post-marketing Surveillance (PMS) study in 500 patients with follow-up period of six months.
This came in line with the proposal presented by the drug maker Allergan India for the additional indication of Dexamethasone Intravitreal Implant 0.7mg "for the treatment of diabetic macular edema".
Diabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the macular area, typically in the inner nuclear, outer plexiform, Henle's fiber layer, and subretinal space.
In addition, the committee noted that the proposed indication is approved by USFDA.
After detailed deliberation, the committee recommended approval of the additional indication "for the treatment of diabetic macular edema" with the condition to conduct an active PMS study in 500 patients with a follow-up period of six months.
Accordingly, the protocol should be submitted within three months of approval of the drug allergen India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.